Global Breast Biopsy Market Size study & Forecast, by Product (Vacuum Assisted Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy), by Image Guided Technology (MRI Guided Breast Biopsy, Ultrasound Guided Breast Biopsy, Mammography Guided Stereotact

Global Breast Biopsy Market Size study & Forecast, by Product (Vacuum Assisted Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy), by Image Guided Technology (MRI Guided Breast Biopsy, Ultrasound Guided Breast Biopsy, Mammography Guided Stereotactic Biopsy, CT Guided Biopsy), by End User (Hospitals and Clinics, Diagnostic Centers) and Regional Analysis, 2022-2029

Global Breast Biopsy Market is valued at approximately USD 691.74 million in 2021 and is anticipated to grow with a healthy growth rate of more than 5.1 % over the forecast period 2022-2029. Breast biopsies can also be used to test for other disorders that are found during a physical examination, however, they are most frequently used to identify breast cancer. Several methods can be used to segment the Breast Biopsy market. One of the least intrusive treatments available, fine needle aspiration biopsy, leaves no scars and is frequently used for breast biopsies. To remove tissue, a needle is inserted into the dermal tissue of the breast. The alternative technique uses ultrasonic radiation to direct the biopsy. The increasing prevalence of breast cancer and the growing Geriatric Population are key factors driving the market growth.

The rising incidences of breast cancer are contributing towards the growth of the Global Breast Biopsy Market. For instance- as per Global Cancer Observatory estimates – in 2020, the total number of breast cancer cases worldwide was estimated at 2.26 million, and this number is projected to reach 2.67 million, and a further 3.03 million in 2040. Furthermore, the increasing number of geriatric individuals is another factor driving the market space. For instance - according to the World Bank Group, the world’s old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 million in 2050. Also, the availability of advantageous reimbursement policies as well as the growing emergence of the liquid biopsy procedures. However, the high Cost of Breast Biopsy procedures coupled with the lack of availability of screening services in developing economies hinders the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Breast Biopsy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of robust healthcare infrastructure as well as increasing incidences of breast cancer in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing investment in healthcare infrastructure in the region would offer lucrative growth opportunities for the market over the forecast period.

Major market player included in this report are:
Zenalux Biomedical Inc.
F. Hoffmann-La Roche Ltd.
OncoCyte Corporation
Laboratory Corporation of America Holdings (Labcorp)
Scion Medical Technologies LLC
Planmed Oy
Aurora Imaging Technology Inc.
Carestream Health
Cardinal Health,
PerkinElmer Inc.

Recent Developments in the Market:
 In March 2021, IZI Medical Products, LLC, one of the leading manufacturers of medical devices used in interventional radiology and interventional oncology procedure announced the launch of its new Quick-Core Auto Biopsy System for soft tissue biopsy.

Global Breast Biopsy Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Image Guided Technology, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product
Vacuum Assisted Biopsy
Core Needle Biopsy
Fine Needle Aspiration Biopsy
By Image Guided Technology
MRI Guided Breast Biopsy
Ultrasound Guided Breast Biopsy
Mammography Guided Stereotactic Biopsy
CT Guided Biopsy
By End User
Hospitals And Clinics
Diagnostic Centers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Zenalux Biomedical Inc.
F. Hoffmann-La Roche Ltd.
OncoCyte Corporation
Laboratory Corporation of America Holdings (Labcorp)
Scion Medical Technologies LLC
Planmed Oy
Aurora Imaging Technology Inc.
Carestream Health
Cardinal Health,
PerkinElmer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.